[Form 4] Silence Therapeutics Plc American Depository Share Insider Trading Activity

Rhea-AI Filing Summary

Silence Therapeutics plc (SLN) – Form 4 insider buying

10% owner Richard Ian Griffiths, via Cream Capital Ltd., disclosed open-market purchases on 21-22 Jul 2025 of 25,345 American Depositary Shares (ADS) at $6.04 and $6.09. Each ADS converts into three ordinary shares, increasing his indirect holding by roughly 76,035 ordinary shares.

Post-trade, Griffiths’ beneficial position totals ≈11.78 million ADS-equivalent shares. No sales were reported. Continued accumulation by a 10% holder generally signals confidence in the company’s outlook and may support sentiment toward SLN shares.

Positive

• 10% owner increased position by 25,345 ADS (~76k ordinary shares), demonstrating confidence.
• No shares were sold, eliminating mixed signals and underscoring a net accumulation stance.

Negative

• None.

Insights

Financial Analyst

TL;DR: Major shareholder adds 25k ADS, modest dollar outlay but positive signal of confidence.

The purchases expand Griffiths’ stake by ~0.2%, costing about US$154k. While immaterial to ownership concentration, insider buying by a long-term 10% holder often reassures investors about near-term prospects and valuation (SLN recently traded near 52-week lows). No derivative complexity or sales dilute the signal. Impact is supportive rather than transformative but leans positive.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Griffiths Richard Ian

(Last) (First) (Middle)

FLOOR 1 LIBERATION STATION

ESPLANADE

(Street)

ST HELIER Y9 JE2 3AS

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Silence Therapeutics plc [ SLN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
American Depositary Shares	$6.04	07/21/2025		P		22,435		(1)	(1)	Ordinary Shares	67,305	(1)	11,781,093	I	See footnote(2)
American Depositary Shares	$6.09	07/22/2025		P		2,910		(1)	(1)	Ordinary Shares	8,730	(1)	11,784,003	I	See footnote(2)

Explanation of Responses:

1. Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date.

2. The securities are held by Cream Capital Limited ("Cream"). Mr. Griffiths is a director and the controlling shareholder of Cream. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

	/s/ Richard Ian Griffiths	07/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many SLN ADS did Richard Ian Griffiths buy?

He purchased 25,345 ADS over two days (22,435 on 21 Jul, 2,910 on 22 Jul 2025).

What was the purchase price for the SLN insider transactions?

ADS were acquired at $6.04 and $6.09 per share.

How many ordinary shares do the new ADS represent?

Each ADS equals three ordinary shares, so the purchase adds ≈76,035 ordinary shares.

What is Richard Ian Griffiths’ total beneficial ownership after the trades?

The filing shows indirect ownership of about 11.78 million ADS-equivalent shares.

Is the Form 4 purchase considered a positive signal for SLN investors?

Insider buying by a 10% owner is typically viewed as positive, suggesting confidence in future performance.